Early detection and treatment of obstructive sleep apnoea in infants with Down syndrome: a prospective, non-randomised, controlled, interventional study.
Behaviour
Down syndrome
Neurocognitive function
Obstructive sleep apnoea
Polysomnography
Journal
The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
received:
26
04
2024
revised:
04
08
2024
accepted:
06
08
2024
medline:
12
9
2024
pubmed:
12
9
2024
entrez:
12
9
2024
Statut:
epublish
Résumé
Infants with Down syndrome (DS) are at high risk of obstructive sleep apnoea (OSA) which is associated with neurocognitive dysfunction and behaviour problems. The aim of our study was to evaluate the effect of early OSA treatment in infants with DS on neurocognitive development and behaviour. In this prospective, interventional, non-randomised study, 40 infants with DS underwent polysomnography (PSG) every 6 months in room air between 6 and 36 months of age ( On the Griffiths III, the total score was significantly higher in the Early diagnosis and treatment of OSA in infants with DS may contribute to a significantly better neurocognitive outcome and behaviour at the age of 36 months. The study was funded by the Jérôme Lejeune Foundation.
Sections du résumé
Background
UNASSIGNED
Infants with Down syndrome (DS) are at high risk of obstructive sleep apnoea (OSA) which is associated with neurocognitive dysfunction and behaviour problems. The aim of our study was to evaluate the effect of early OSA treatment in infants with DS on neurocognitive development and behaviour.
Methods
UNASSIGNED
In this prospective, interventional, non-randomised study, 40 infants with DS underwent polysomnography (PSG) every 6 months in room air between 6 and 36 months of age (
Findings
UNASSIGNED
On the Griffiths III, the total score was significantly higher in the
Interpretation
UNASSIGNED
Early diagnosis and treatment of OSA in infants with DS may contribute to a significantly better neurocognitive outcome and behaviour at the age of 36 months.
Funding
UNASSIGNED
The study was funded by the Jérôme Lejeune Foundation.
Identifiants
pubmed: 39262447
doi: 10.1016/j.lanepe.2024.101035
pii: S2666-7762(24)00202-3
pmc: PMC11387522
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101035Informations de copyright
© 2024 The Author(s).
Déclaration de conflit d'intérêts
None of the authors had a conflict of interest to declare. A medical writer provided writing and editing assistance, which was funded through the Jérôme Lejeune Foundation.